Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and market positioning. Core Insights - The company achieved a revenue of 4.535 billion yuan in 2024, representing a year-over-year growth of 15.41%. The net profit attributable to the parent company was 1.828 billion yuan, with a growth of 10.57% year-over-year [1][2] - The increase in the proportion of large machines has been a significant driver for both domestic and international business growth. In the domestic market, revenue reached 2.849 billion yuan, growing by 9.24% year-over-year, while international revenue was 1.686 billion yuan, with a substantial growth of 27.60% year-over-year [2] - The company is focusing on enhancing its product matrix and aims to become a comprehensive laboratory solution provider. Significant investments in R&D have been made to maintain a competitive edge in the high-end luminescence field [2] - The forecast for revenue from 2025 to 2027 is projected to be 5.163 billion yuan, 6.074 billion yuan, and 7.220 billion yuan, with corresponding year-over-year growth rates of 13.8%, 17.7%, and 18.9% respectively [2][3] Financial Summary - In 2024, the total revenue was 4.535 billion yuan, with a year-over-year growth rate of 15.4%. The net profit attributable to the parent company was 1.828 billion yuan, reflecting a growth rate of 10.6% [3] - The gross profit margin is expected to be around 70.4% in 2025, with a projected return on equity (ROE) of 21.2% [3] - Earnings per share (EPS) are forecasted to be 2.56 yuan in 2025, with a price-to-earnings (P/E) ratio of 20.46 [3]

Core Insights - The Yumen Oilfield, known for being the site of China's first oil well, is now focusing on the transition to clean energy and the development of new energy projects [2][3] - The company has established a 300 MW photovoltaic power station, which includes a storage battery area to manage excess electricity generated [1][3] - The new energy sector at Yumen Oilfield has seen significant growth, with a new storage capacity of 85 MW and 260 MWh [3][4] Company Development - The company has implemented a dual mentorship and training mechanism to enhance employee skills, which has proven effective for new hires like Tian Yuxin [2][3] - Tian Yuxin, a recent graduate, has quickly adapted to the demands of the job, gaining hands-on experience through various roles within the company [2][3] - The company emphasizes practical learning, with employees like Tian Yuxin participating in rigorous training and operational tasks [3][4] Technological Advancements - The company has developed an integrated operation and maintenance plan for photovoltaic and energy storage systems, optimizing discharge strategies across all new energy projects [4] - Innovations in cooling systems for battery storage have been explored, contributing to improved operational protocols and management experience [4] - The successful commissioning of the photovoltaic power station marks a significant milestone in the company's transition to renewable energy [3][4]

编写火箭燃料加注方案，与设计院沟通发射场二期项目建设细节……工作仅两年，海南国际商业航天发 射有限公司总体技术部加注供气系统工程师王舒皓已成为一名业务"多面手"。"有幸搭上商业航天发展 快车，才获得了更多锻炼机会。"生于1997年的王舒皓说。 航天梦，要追溯到儿时。他的家乡距离太原卫星发射中心约100公里。"小时候，看到火箭发射后空中留 下的白烟，我会兴奋得直拍手。"2022年底，在大学学习动力工程的王舒皓，看到海南商发的招聘信 息，毫不犹豫投了简历，并于次年4月入职。 发射场的二号工位创新采用"通用型"接口设计，可兼容多家公司20个型号的火箭。但在工位建设期间， 有的新型火箭尚在设计，海南商发就必须提前收集需求。"一旦火箭方的某一项指标出现偏差，发射场 王舒皓正在检查设备。 本报记者 曹文轩摄 海南商业航天发射场。 新华社记者 蒲晓旭摄 的建设成本可能就会大幅增加。这时，就要遵循商业航天的'商业逻辑'，多方反复论证，寻找最经济、 安全的方案。"王舒皓介绍，在这一过程中，自己的学习能力、沟通能力都得到提升。 2024年，商业航天被写入《政府工作报告》。多地出台支持政策，加速布局商业航天产业。"整个行业 都充满 ...

Group 1 - The article emphasizes the importance of the younger generation in driving innovation and contributing to national development, particularly in emerging industries [1] - Young professionals are increasingly taking on key roles in various sectors, including maritime safety, commercial aerospace, and clean energy systems [1] - The series "Young People in New Industries" aims to highlight the contributions of young individuals in these fields and their impact on societal progress [1] Group 2 - The China Shipbuilding Industry Corporation has developed a predictive health management system (PHM) for low-speed marine engines, enhancing safety and operational efficiency for ocean-going vessels [2] - The project faced challenges such as data collection and transmission issues, as well as discrepancies between simulation results and real-world testing due to limited sample data [4] - The successful implementation of PHM marks a significant advancement in the maritime industry, with the system being commercially applied for the first time in China [4] Group 3 - The development of low-carbon and zero-carbon engines, such as ammonia-fueled engines, is gaining momentum, with increasing demand for skilled professionals in this area [5] - The precision required for manufacturing components of these engines is extremely high, necessitating an accuracy of 0.01 millimeters [5] - The industry is optimistic about attracting more young talent to contribute to the growth of sustainable maritime technologies [5]

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 新产业(300832) 投资评级 上次评级 [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_Title] 大型机占比持续提升，收入展现增长韧性 [Table_ReportDate] 2025 年 05 月 02 日 [Table_S 事件：公司发布 ummary]2024 年年报和 2025 年一季报，2024 年实现营业收入 45.35 亿元（yoy+15.41%），归母净利润 18.28 亿元（yoy+10.57%），扣非归母 净利润 17.20 亿元（yoy+11.19%），经营活动产生的现金流量净额 13.56 亿 元（yoy-4.36%）。2025Q1 实现营业收入 11.25 亿元（yoy+10.12%），归 母净利润 4.38 亿元（yoy+ ...

深圳市新产业生物医学工程股份有限公司 深圳市新产业生物医学工程股份有限公司 投资者关系活动记录表 证券代码：300832 证券简称：新产业 编号：2025-004 投资者关系活动记录表 | 投资者关系 | □媒体采访 ☑业绩说明会 | | --- | --- | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | ☑其他 线上交流 | | 参与单位名 | 共计 120 家机构，163 名参会人员，详见附件《与会机构名单》； | | 称及人员姓 | 以及通过深交所"互动易"平台"云访谈"栏目参加新产业 2024 | | 名 | 年度业绩说明会的全体投资者 | | 时间 | 年 月 日-4 月 日 2025 4 27 30 | | | 23 | | | 栏目 | | 待人员姓名 | 副总经理兼财务总监 丁晨柳 | | | 独立董事 伍前辉 | | | 投资者关系负责人 吕宇宁 | | | 公司于 月 日发布了《2024 年年度报告》《2025 4 26 | | | 了线上和线下交流，本次交流涉及的经营要点及主要互动提问 | | 投资者关系 | | | 活动主要内 | 一、公司 年度及 ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 日本特许厅颁发的1项《发明专利证书》，现将本次取得的发明专利具体情况公 告如下： 证券代码：300832 证券简称：新产业 公告编号：2025-038 深圳市新产业生物医学工程股份有限公司 关于公司获得发明专利证书的公告 专利权人：深圳市新产业生物医学工程股份有限公司 发明人：慕海林、徐方园、仇泽峰、程昱、黄任 专利申请日：2023年11月20日 深圳市新产业生物医学工程股份有限公司 发明名称：输送装置及核酸检测装置 日本专利号：第7663662号 授权公告日：2025年04月08日 上述专利保护技术为公司自主研发，本发明应用于全自动核酸检测分析系统 Molecision R8，涉及一种耗材输送装置，通过设置可横向移动的活动板以及可相 对于活动板沿竖向移动的第一承载台，使得本装置能够兼容不同高度的耗材，并 且能够实现耗材在载料位置和取料位置间的快速转移，大幅提高了耗材的转移效 率，进而提高了全自动核酸检测仪的检测速度。 本次取得的发明专利不会对公 ...

2025 年 4 月 30 日 公司研究 24 年营收稳步增长，创新成果不断涌现 研发投入持续加大，创新成果不断涌现：公司始终重视研发创新，2024 年研发 投入 4.54 亿元，同比增长 23.92%。持续的高投入为公司技术创新提供了坚实 保障。24 年公司在仪器和试剂研发方面成果丰硕，如更高通量的 MAGLUMIX10 化学发光免疫分析仪器发布；具有完全自主知识产权的开放式全自动样品处理系 统 SATLARST8 和智慧实验室平台 iXLAB 正式上市。众多新产品的推出和技术突 破，有助于公司进一步提升市场竞争力，巩固行业领先地位。 国内国际市场双轮驱动，市场份额逐步扩大：国内市场方面，公司通过持续推广 高速化学发光免疫分析仪及流水线产品，深化与国内大型医疗终端的合作，截至 2024 年末，国内三级医院客户达 1732 家，三级医院覆盖率为 44.93%。海外市 场上，公司通过区域化运营和本地化深耕，品牌国际影响力不断提升，公司已在 14 个核心国家建立运营体系，这些本地化的分支机构正成为区域业务增长的强 力引擎。 盈利预测、估值与评级：考虑到行业政策可能对公司带来的影响，我们下调公司 25-26 年的 ...

Core Insights - The company reported a revenue of 4.535 billion yuan for 2024, a year-on-year increase of 15.41%, driven by growth in overseas market sales [1] - The net profit attributable to shareholders was 1.828 billion yuan, up 10.57% year-on-year, while the non-recurring net profit was 1.720 billion yuan, an increase of 11.19% [1] - In Q4 2024, the company achieved a revenue of 1.121 billion yuan, a 9.75% increase year-on-year, but the net profit decreased by 4.73% to 445 million yuan [1] Revenue Breakdown - Domestic revenue reached 2.843 billion yuan, a 9.32% increase, primarily due to reagent price adjustments post-collection [2] - Overseas revenue was 1.684 billion yuan, a significant growth of 27.67%, with reagent income increasing by 26.47% [2] - The company established subsidiaries in Indonesia, Malaysia, and Thailand, and opened an office in Hanoi, Vietnam, with a successful launch of a subsidiary in South Korea in early 2025 [2] Product Performance - The flagship model MAGLUMI X8 saw stable growth, with annual sales of 1,048 units, bringing the total installed base to 3,701 units by the end of 2024 [2] - The SATLARS T8 fully automated laboratory automation line was successfully launched in June 2024, achieving 87 installations in its first year [3] Financial Metrics - The overall gross margin for 2024 was 72.07%, a slight decrease of 0.89 percentage points year-on-year [4] - The net profit margin decreased by 1.76 percentage points to 40.32% due to various cost factors [4] - In Q4 2024, the gross margin was 71.26%, with a notable decline influenced by accelerated installations of large equipment [4] Future Projections - Revenue forecasts for 2025-2027 are 5.155 billion, 6.010 billion, and 6.810 billion yuan, with year-on-year growth rates of 14%, 17%, and 13% respectively [5] - Projected net profits for the same period are 2.023 billion, 2.422 billion, and 2.794 billion yuan, reflecting growth rates of 11%, 20%, and 15% [5] - Earnings per share (EPS) are expected to be 2.57, 3.08, and 3.56 for 2025, 2026, and 2027 respectively [5]

Investment Highlights - The report highlights the recovery of revenue growth for Yuyue Medical, with a significant increase in overseas sales, achieving a revenue of 7.57 billion yuan in 2024, down 5.1% year-on-year, and a net profit of 1.81 billion yuan, down 24.6% year-on-year [3][8] - Guotai Group's performance shows resilience in its civil explosives business, with a non-net profit growth of 17.09% year-on-year in Q1 2025, despite a slight revenue decline of 1.26% [12][13] - China Merchants Highway reported a revenue of approximately 2.803 billion yuan in Q1 2025, down 7.24% year-on-year, but net profit improved by 2.74% due to cost control and increased investment income [16][17] - Shenzhen Gas's main business in urban gas sales showed growth, with a revenue of 28.348 billion yuan in 2024, down 8.34% year-on-year, but a net profit increase of 1.19% [21][22] - New Industry's overseas business continued to grow rapidly, with a revenue of 4.535 billion yuan in 2024, up 15.41% year-on-year, and a net profit of 1.828 billion yuan, up 10.57% [25][26] - Huali Group's revenue in Q1 2025 grew by 12% year-on-year, driven by new brand collaborations and strong sales of sports shoes [30][31] - Bohai Leasing, a leading aircraft leasing company, reported a significant increase in aircraft sales revenue, reaching 12.7 billion yuan in 2024, up 61.08% year-on-year, driven by a strong aircraft market [35][36] - Weimao Electronics, an industrial intelligent connection control solution manufacturer, achieved a revenue of 260 million yuan in 2024, up 13.69% year-on-year, with a focus on expanding into emerging fields [39][40] Company-Specific Summaries Yuyue Medical (002223.SZ) - The company experienced a revenue decline in 2024 due to high base effects from the previous year, but Q1 2025 showed a recovery with a 9.2% year-on-year increase in revenue [3][9] - The product mix has led to a slight decrease in gross margin, with a 50.1% gross margin in 2024, down 1.2 percentage points year-on-year [10] - The company maintains a strong financial position with 7.08 billion yuan in cash and no short-term or long-term loans [10] Guotai Group (603977.SH) - The civil explosives business showed growth, with a revenue of 327 million yuan in Q1 2025, up 1.4% year-on-year [13][14] - The company faced a decline in electronic detonator sales but saw an increase in explosive engineering revenue [14][15] - The gross margin for Q1 2025 was 32.72%, down 0.5 percentage points year-on-year, but the non-net profit remained stable [15] China Merchants Highway (001965.SZ) - The company is actively pursuing expansion projects, including the ongoing reconstruction of key highways [17][18] - The net profit forecast for 2025-2027 is expected to grow steadily, with projected profits of 5.74 billion yuan in 2025 [18] Shenzhen Gas (601139.SH) - The urban gas sales volume increased by 2.78% in 2024, with significant growth in the Greater Bay Area [22] - The company is expected to benefit from lower upstream gas prices and increased sales volume [22][24] New Industry (300832.SZ) - The company reported a strong performance in overseas markets, with a 27.67% increase in overseas revenue [27] - The gross margin for 2024 was 72.26%, with a focus on expanding the product lineup in the chemical luminescence sector [28] Huali Group (300979.SZ) - The company maintained a strong partnership with major brands, resulting in a 12.34% revenue increase in Q1 2025 [30][31] - The company is expanding production capacity to meet growing demand, with a workforce increase of 17% [31] Bohai Leasing (000415.SZ) - The company is positioned as a global leader in aircraft leasing, with a fleet size of 1,158 aircraft [36] - The net profit forecast for 2025-2027 is expected to grow significantly, with a projected profit of 1.913 billion yuan in 2025 [37] Weimao Electronics (833346.BJ) - The company is focusing on the automotive and industrial automation sectors, with a projected growth in the vehicle wiring harness market [40][41] - The company is expanding its production capabilities to meet increasing demand in emerging markets [41]